Close

Form 10-Q European Biotech Acquisi For: Jun 30

August 15, 2022 5:39 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
falseQ20001841258--12-3100-000000000000 0001841258 2022-01-01 2022-06-30 0001841258 2021-01-08 2021-06-30 0001841258 2021-04-01 2021-06-30 0001841258 2022-04-01 2022-06-30 0001841258 2021-12-31 0001841258 2022-06-30 0001841258 2021-01-08 2021-03-31 0001841258 2022-01-01 2022-03-31 0001841258 2021-01-07 0001841258 2021-06-30 0001841258 2021-03-31 0001841258 2022-03-31 0001841258 us-gaap:CommonClassAMember 2022-06-30 0001841258 ebac:DerivativeWarrantLiabilitiesPublicMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001841258 ebac:DerivativeWarrantLiabilitiesPrivateMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001841258 ebac:DerivativeWarrantLiabilitiesPublicMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001841258 ebac:DerivativeWarrantLiabilitiesPrivateMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001841258 ebac:DerivativeWarrantLiabilitiesPrivateMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0001841258 ebac:DerivativeWarrantLiabilitiesPublicMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001841258 us-gaap:CommonClassBMember 2022-06-30 0001841258 ebac:PublicWarrantsMember 2022-06-30 0001841258 ebac:ClassAOrdinarySharesIncludingSubjectToPossibleRedemptionMember 2022-06-30 0001841258 ebac:SponsorMember 2022-06-30 0001841258 ebac:PublicWarrantsMember ebac:ProspectiveRedemptionOfWarrantsMember 2022-06-30 0001841258 ebac:ClassAOrdinarySharesIncludingSubjectToPossibleRedemptionMember ebac:SponsorMember 2022-06-30 0001841258 us-gaap:PrivatePlacementMember 2022-06-30 0001841258 ebac:AssetHeldInTrustsMember 2022-06-30 0001841258 ebac:RedemptionTriggerPriceTwoMember ebac:ProspectiveRedemptionOfWarrantsMember ebac:PublicWarrantsMember 2022-06-30 0001841258 ebac:RedemptionTriggerPriceOneMember ebac:ProspectiveRedemptionOfWarrantsMember ebac:PublicWarrantsMember 2022-06-30 0001841258 ebac:PrivatePlacementWarrantsMember ebac:RedemptionTriggerPriceOneMember ebac:ProspectiveRedemptionOfWarrantsMember 2022-06-30 0001841258 ebac:ProspectiveRedemptionOfWarrantsMember ebac:PrivatePlacementWarrantsMember 2022-06-30 0001841258 ebac:BusinessCombinationMember 2022-06-30 0001841258 us-gaap:PrivatePlacementMember us-gaap:CommonClassAMember 2022-06-30 0001841258 ebac:ConversionOfClassBCommonStockIntoClassACommonStockMember ebac:SponsorMember 2022-06-30 0001841258 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-06-30 0001841258 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001841258 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-06-30 0001841258 ebac:AdministrativeSupportAgreementMember 2022-06-30 0001841258 us-gaap:CommonStockSubjectToMandatoryRedemptionMember 2022-06-30 0001841258 ebac:SponsorMember ebac:WorkingCapitalLoansMember 2022-06-30 0001841258 us-gaap:CommonClassAMember 2021-12-31 0001841258 ebac:DerivativeWarrantLiabilitiesPublicMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001841258 ebac:DerivativeWarrantLiabilitiesPrivateMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001841258 ebac:DerivativeWarrantLiabilitiesPrivateMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001841258 ebac:DerivativeWarrantLiabilitiesPrivateMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001841258 ebac:DerivativeWarrantLiabilitiesPublicMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001841258 ebac:DerivativeWarrantLiabilitiesPublicMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001841258 us-gaap:CommonClassBMember 2021-12-31 0001841258 ebac:PrivatePlacementWarrantsMember 2021-12-31 0001841258 ebac:ClassAOrdinarySharesIncludingSubjectToPossibleRedemptionMember 2021-12-31 0001841258 ebac:ClassAOrdinarySharesIncludingSubjectToPossibleRedemptionMember ebac:SponsorMember 2021-12-31 0001841258 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001841258 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001841258 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001841258 ebac:AdministrativeSupportAgreementMember 2021-12-31 0001841258 us-gaap:CommonStockSubjectToMandatoryRedemptionMember 2021-12-31 0001841258 ebac:SponsorMember ebac:WorkingCapitalLoansMember 2021-12-31 0001841258 us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001841258 us-gaap:CommonClassBMember 2022-01-01 2022-06-30 0001841258 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001841258 us-gaap:CapitalUnitsMember 2022-01-01 2022-06-30 0001841258 ebac:PublicWarrantsMember 2022-01-01 2022-06-30 0001841258 ebac:PublicWarrantsMember us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001841258 us-gaap:OverAllotmentOptionMember 2022-01-01 2022-06-30 0001841258 us-gaap:OverAllotmentOptionMember us-gaap:PrivatePlacementMember 2022-01-01 2022-06-30 0001841258 ebac:PrivatePlacementWarrantsMember ebac:ProspectiveRedemptionOfWarrantsMember 2022-01-01 2022-06-30 0001841258 ebac:AssetHeldInTrustsMember 2022-01-01 2022-06-30 0001841258 ebac:ProspectiveRedemptionOfWarrantsMember ebac:RedemptionTriggerPriceOneMember ebac:PublicWarrantsMember 2022-01-01 2022-06-30 0001841258 ebac:ProspectiveRedemptionOfWarrantsMember ebac:RedemptionTriggerPriceTwoMember ebac:PublicWarrantsMember 2022-01-01 2022-06-30 0001841258 ebac:PrivatePlacementWarrantsMember ebac:RedemptionTriggerPriceOneMember ebac:ProspectiveRedemptionOfWarrantsMember 2022-01-01 2022-06-30 0001841258 ebac:AssetsHeldInTrustMember 2022-01-01 2022-06-30 0001841258 ebac:BusinessCombinationMember 2022-01-01 2022-06-30 0001841258 ebac:AssetHeldInTrustsMember ebac:SponsorMember 2022-01-01 2022-06-30 0001841258 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-01-01 2022-06-30 0001841258 us-gaap:PrivatePlacementMember 2022-01-01 2022-06-30 0001841258 ebac:SponsorMember 2022-01-01 2022-06-30 0001841258 ebac:RelatedPartyLoansMember 2022-01-01 2022-06-30 0001841258 ebac:SponsorMember ebac:AdministrativeSupportAgreementMember 2022-01-01 2022-06-30 0001841258 us-gaap:CommonStockSubjectToMandatoryRedemptionMember 2022-01-01 2022-06-30 0001841258 ebac:NonRedeemableClassAAndClassBOrdinarySharesMember 2022-01-01 2022-06-30 0001841258 ebac:ClassaordinarysharessubjecttopossibleredemptionMember 2022-01-01 2022-06-30 0001841258 ebac:PublicAndPrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-01-08 2021-03-31 0001841258 us-gaap:PrivatePlacementMember 2021-01-08 2021-03-31 0001841258 ebac:PublicWarrantsMember 2021-01-08 2021-03-31 0001841258 us-gaap:RetainedEarningsMember 2021-01-08 2021-03-31 0001841258 us-gaap:AdditionalPaidInCapitalMember 2021-01-08 2021-03-31 0001841258 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-01-08 2021-03-31 0001841258 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-01-08 2021-03-31 0001841258 us-gaap:WarrantMember us-gaap:CommonClassAMember 2021-01-08 2021-03-31 0001841258 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001841258 ebac:NonRedeemableClassAAndClassBOrdinarySharesMember 2022-01-01 2022-03-31 0001841258 us-gaap:FairValueInputsLevel3Member ebac:PublicAndPrivateWarrantsMember 2021-03-18 2021-03-18 0001841258 us-gaap:OverAllotmentOptionMember us-gaap:CommonClassAMember 2021-03-18 2021-03-18 0001841258 us-gaap:IPOMember us-gaap:CommonClassAMember 2021-03-18 2021-03-18 0001841258 us-gaap:FairValueInputsLevel3Member ebac:PublicAndPrivateWarrantsMember 2021-03-18 0001841258 us-gaap:IPOMember us-gaap:CommonClassAMember 2021-03-18 0001841258 us-gaap:FairValueInputsLevel3Member ebac:PublicAndPrivateWarrantsMember 2021-05-03 2021-05-03 0001841258 us-gaap:OverAllotmentOptionMember 2021-05-03 2021-05-03 0001841258 us-gaap:PrivatePlacementMember ebac:SponsorMember 2021-05-03 2021-05-03 0001841258 us-gaap:PrivatePlacementMember 2021-05-03 2021-05-03 0001841258 us-gaap:CommonClassBMember us-gaap:OverAllotmentOptionMember 2021-05-03 2021-05-03 0001841258 ebac:SponsorMember ebac:PrivatePlacementTwoMember 2021-05-03 2021-05-03 0001841258 us-gaap:PrivatePlacementMember us-gaap:CommonClassAMember 2021-03-08 2021-03-08 0001841258 ebac:AssetHeldInTrustsMember 2021-03-08 2021-03-08 0001841258 ebac:SponsorMember us-gaap:OverAllotmentOptionMember 2021-05-04 2021-05-04 0001841258 us-gaap:OverAllotmentOptionMember 2021-05-04 0001841258 us-gaap:OverAllotmentOptionMember 2021-04-29 2021-04-29 0001841258 ebac:PublicWarrantsMember us-gaap:CommonClassAMember 2021-09-30 0001841258 ebac:SponsorMember 2021-09-30 0001841258 ebac:SponsorMember 2021-01-18 2021-01-18 0001841258 us-gaap:CommonClassAMember ebac:SponsorMember 2021-03-15 2021-03-15 0001841258 ebac:SponsorMember ebac:IndependentDirectorsMember 2021-03-15 2021-03-15 0001841258 ebac:FounderSharesMember 2021-03-15 2021-03-15 0001841258 us-gaap:OverAllotmentOptionMember 2021-03-15 2021-03-15 0001841258 ebac:SponsorMember ebac:FounderSharesMember 2021-03-15 2021-03-15 0001841258 ebac:SponsorMember us-gaap:CommonClassAMember 2021-03-15 0001841258 ebac:FounderSharesMember 2021-03-15 0001841258 us-gaap:FairValueInputsLevel3Member ebac:PublicAndPrivateWarrantsMember 2021-05-03 0001841258 us-gaap:OverAllotmentOptionMember 2021-05-03 0001841258 ebac:PrivatePlacementTwoMember ebac:SponsorMember 2021-05-03 0001841258 ebac:SponsorMember 2021-06-30 0001841258 us-gaap:CommonClassAMember 2021-12-31 2021-12-31 0001841258 us-gaap:CommonClassBMember 2022-04-01 2022-06-30 0001841258 us-gaap:CommonClassAMember 2022-04-01 2022-06-30 0001841258 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001841258 ebac:SponsorMember ebac:AdministrativeSupportAgreementMember 2022-04-01 2022-06-30 0001841258 ebac:ClassaordinarysharessubjecttopossibleredemptionMember 2022-04-01 2022-06-30 0001841258 us-gaap:CommonClassBMember 2021-04-01 2021-06-30 0001841258 us-gaap:CommonClassAMember 2021-04-01 2021-06-30 0001841258 ebac:PublicWarrantsMember us-gaap:OverAllotmentOptionMember 2021-04-01 2021-06-30 0001841258 ebac:PrivatePlacementWarrantsMember us-gaap:OverAllotmentOptionMember 2021-04-01 2021-06-30 0001841258 ebac:PublicWarrantsMember 2021-04-01 2021-06-30 0001841258 ebac:PrivatePlacementWarrantsMember 2021-04-01 2021-06-30 0001841258 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001841258 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-04-01 2021-06-30 0001841258 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001841258 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-04-01 2021-06-30 0001841258 ebac:SponsorMember ebac:AdministrativeSupportAgreementMember 2021-04-01 2021-06-30 0001841258 us-gaap:CommonClassBMember us-gaap:OverAllotmentOptionMember 2021-04-01 2021-06-30 0001841258 ebac:NonRedeemableClassAAndClassBOrdinarySharesMember 2021-04-01 2021-06-30 0001841258 ebac:ClassaordinarysharessubjecttopossibleredemptionMember 2021-04-01 2021-06-30 0001841258 ebac:SponsorMember 2022-03-31 2022-03-31 0001841258 us-gaap:CommonClassBMember 2021-01-08 2021-06-30 0001841258 us-gaap:CommonClassAMember 2021-01-08 2021-06-30 0001841258 us-gaap:IPOMember 2021-01-08 2021-06-30 0001841258 ebac:AfterClosureOfInitialPublicOfferMember ebac:PublicWarrantsMember 2021-01-08 2021-06-30 0001841258 ebac:AfterCompletionOfBusinessCombinationMember ebac:PublicWarrantsMember 2021-01-08 2021-06-30 0001841258 ebac:PublicWarrantsMember 2021-01-08 2021-06-30 0001841258 ebac:PublicWarrantsMember ebac:ProspectiveRedemptionOfWarrantsMember 2021-01-08 2021-06-30 0001841258 ebac:SponsorMember ebac:AdministrativeSupportAgreementMember 2021-01-08 2021-06-30 0001841258 ebac:AssetsHeldInTrustMember 2021-01-08 2021-06-30 0001841258 ebac:NonRedeemableClassAAndClassBOrdinarySharesMember 2021-01-08 2021-06-30 0001841258 ebac:ClassaordinarysharessubjecttopossibleredemptionMember 2021-01-08 2021-06-30 0001841258 us-gaap:CommonClassAMember 2022-06-30 2022-06-30 0001841258 us-gaap:CommonClassBMember 2021-01-01 2021-12-31 0001841258 us-gaap:CommonStockSubjectToMandatoryRedemptionMember 2021-01-01 2021-12-31 0001841258 us-gaap:CommonClassBMember 2022-08-15 0001841258 us-gaap:CommonClassAMember 2022-08-15 0001841258 us-gaap:FairValueInputsLevel3Member 2021-01-07 0001841258 us-gaap:RetainedEarningsMember 2021-01-07 0001841258 us-gaap:AdditionalPaidInCapitalMember 2021-01-07 0001841258 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-01-07 0001841258 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-01-07 0001841258 us-gaap:RetainedEarningsMember 2021-03-31 0001841258 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001841258 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-03-31 0001841258 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-03-31 0001841258 ebac:PublicAndPrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001841258 us-gaap:RetainedEarningsMember 2021-12-31 0001841258 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001841258 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-12-31 0001841258 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-12-31 0001841258 us-gaap:RetainedEarningsMember 2022-03-31 0001841258 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001841258 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001841258 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 0001841258 us-gaap:RetainedEarningsMember 2022-06-30 0001841258 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-06-30 0001841258 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-06-30 0001841258 us-gaap:RetainedEarningsMember 2021-06-30 0001841258 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-06-30 0001841258 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-06-30 iso4217:USD xbrli:shares xbrli:pure utr:Year utr:Month utr:Day iso4217:USD xbrli:shares ebac:Directors
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
                    
to
                    
Commission File Number:
001-40211
 
 
European Biotech Acquisition Corp.
(Exact name of registrant as specified in its charter)
 
 
 
Cayman Islands
 
N/A
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
Johannes Vermeerplein 9
1071 DV Amsterdam, Netherlands
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 31 (0) 20 664 55 00
Not Applicable
(Former name or former address, if changed since last report)
 
 
Securities registered pursuant to Section 12(b) of the Act:                 
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Units, each consisting of one Class A Ordinary Share and
one-third
of one Redeemable Warrant
 
EBACU
 
The NASDAQ Stock Market LLC
Class A Ordinary Shares, par value $0.0001 per share
 
EBAC
 
The NASDAQ Stock Market LLC
Warrants, each whole warrant exercisable for one Class A Ordinary Share for $11.50 per share
 
EBACW
 
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer      Accelerated filer  
Non-accelerated
filer
     Smaller reporting company  
     Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    Yes      No  ☐
As of August 15, 2022, 13,209,880 Class A ordinary shares, par value $0.0001, and 3,188,696 Class B ordinary shares, par value $0.0001, were issued and outstanding.
 
 
 

EUROPEAN BIOTECH ACQUISITION CORP.
Quarterly Report on Form
10-Q
For The Three Months Ended June 30, 2022
Table of Contents
 
    
Page

No.
 
  
Item 1.
  Condensed Financial Statements      1  
  Condensed Balance Sheets as of June 30, 2022 (Unaudited) and December 31, 2021      1  
  Condensed Statements of Operations for the Three and Six Months Ended June 30, 2022, the Three Months Ended June 30, 2021 and for the Period from January 8, 2021 (Inception) through June 30, 2021 (Unaudited)      2  
  Condensed Statements of Changes in Shareholders’ Deficit for the Three and Six Months Ended June 30, 2022, the Three Months Ended June 30, 2021 and for the Period from January 8, 2021 (Inception) through June 30, 2021 (Unaudited)      3  
  Condensed Statements of Cash Flows for the Six Months Ended June 30, 2022 and for the Period from January 8, 2021 (Inception) through June 30, 2021 (Unaudited)      4  
  Notes to Unaudited Condensed Financial Statements      5  
Item 2.
  Management’s Discussion and Analysis of Financial Condition and Results of Operations      21  
Item 3.
  Quantitative and Qualitative Disclosures About Market Risk      25  
Item 4.
  Controls and Procedures      25  
  
Item 1.
  Legal Proceedings      25  
Item 1A.
  Risk Factors      26  
Item 2.
  Unregistered Sales of Equity Securities and Use of Proceeds      27  
Item 3.
  Defaults Upon Senior Securities      27  
Item 4.
  Mine Safety Disclosures      27  
Item 5.
  Other Information      27  
Item 6.
  Exhibits      27  
     28  

PART I - FINANCIAL INFORMATION
Item 1. Condensed Financial Statements
EUROPEAN BIOTECH ACQUISITION CORP.
CONDENSED BALANCE SHEETS
 
    
June 30, 2022
   
December 31, 2021
 
    
(Unaudited)
       
Assets
                
Current assets:
                
Cash
   $ 308,103     $ 868,280  
Prepaid expenses
     175,651       48,190  
    
 
 
   
 
 
 
Total current assets
     483,754       916,470  
Investments held in Trust Account
     127,741,378       127,556,289  
    
 
 
   
 
 
 
Total Assets
  
$
128,225,132
 
 
$
128,472,759
 
    
 
 
   
 
 
 
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit:
                
Current liabilities:
                
Accounts payable
   $ 131,283     $ 57,906  
Accrued expenses
     305,230       447,295  
    
 
 
   
 
 
 
Total current liabilities
     436,513       505,201  
Derivative warrant liabilities
     479,850       2,641,980  
Deferred legal fees
     271,606           
Deferred underwriting commissions
     4,464,174       4,464,174  
    
 
 
   
 
 
 
Total liabilities
     5,652,143       7,611,355  
    
 
 
   
 
 
 
Commitments and Contingencies
                
Class A ordinary shares subject to possible redemption, $0.0001 par value; 12,754,784 shares at $10.007 and $10.000 per share as of June 30, 2022 and December 31, 2021, respectively
     127,641,379       127,547,840  
Shareholders’ Deficit:
                
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding as of June 30, 2022 and December 31, 2021
                  
Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 455,096 shares issued and outstanding (excluding 12,754,784 shares subject to possible redemption) as of June 30, 2022 and December 31, 2021
     46       46  
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,188,696 shares issued and outstanding as of June 30, 2022 and December 31, 2021
     319       319  
Additional
paid-in
capital
                  
Accumulated deficit
     (5,068,755 )     (6,686,801
    
 
 
   
 
 
 
Total shareholders’ deficit
     (5,068,390     (6,686,436
    
 
 
   
 
 
 
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit
  
$
128,225,132
 
 
$
128,472,759
 
    
 
 
   
 
 
 
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
1

EUROPEAN BIOTECH ACQUISITION CORP.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
    
For The Three Months Ended
June 30,
   
For The Six
Months Ended
June 30, 2022
   
For The Period
From January 8,
2021 (Inception)
Through June 30,
2021
 
  
2022
   
2021
 
General and administrative expenses
   $ 312,369     $ 134,810     $ 515,634     $ 224,660  
General and administrative expenses - related party
     60,000       60,000       120,000       80,000  
    
 
 
   
 
 
   
 
 
   
 
 
 
Loss from operations
     (372,369 )     (194,810     (635,634 )     (304,660
Other income (expenses):
                                
Change in fair value of derivative warrant liabilities
     400,810       680,290       2,162,130       1,343,760  
Income from investments held in Trust Account
     172,244       4,110       185,089       4,110  
Offering costs associated with derivative warrant liabilities
              (16,066              (314,846
    
 
 
   
 
 
   
 
 
   
 
 
 
Net income
   $ 200,685     $ 473,524     $ 1,711,585     $ 728,364  
    
 
 
   
 
 
   
 
 
   
 
 
 
Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted
     12,754,784       12,489,365       12,754,784       7,497,312  
    
 
 
   
 
 
   
 
 
   
 
 
 
Basic and diluted net income per share, Class A ordinary shares subject to possible redemption
   $ 0.01     $ 0.03     $ 0.10     $ 0.07  
    
 
 
   
 
 
   
 
 
   
 
 
 
Weighted average shares outstanding of
non-redeemable
Class A ordinary shares and Class B ordinary shares, basic
     3,643,792       3,449,788       3,643,792       3,098,222  
    
 
 
   
 
 
   
 
 
   
 
 
 
Basic net income per share,
non-redeemable
Class A ordinary shares and Class B ordinary shares
   $ 0.01     $ 0.03     $ 0.10     $ 0.07  
    
 
 
   
 
 
   
 
 
   
 
 
 
Weighted average shares outstanding of
non-redeemable
Class A ordinary shares and Class B ordinary shares, diluted
     3,643,792       3,455,096       3,643,792       3,455,096  
    
 
 
   
 
 
   
 
 
   
 
 
 
Diluted net income per share,
non-redeemable
Class A ordinary shares and Class B ordinary shares
   $ 0.01     $ 0.03     $ 0.10     $ 0.07  
    
 
 
   
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
2

EUROPEAN BIOTECH ACQUISITION CORP.
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 (UNAUDITED)

 
 
  
Ordinary Shares
 
  
Additional
 
  
 
 
 
Total
 
 
  
Class A
 
  
Class B
 
  
Paid-in
 
  
Accumulated
 
 
Shareholders’
 
 
  
Shares
 
  
Amount
 
  
Shares
 
  
Amount
 
  
Capital
 
  
Deficit
 
 
Deficit
 
Balance - December 31, 2021
  
 
455,096
 
  
$
46
 
  
 
3,188,696
 
  
$
319
 
  
$
  
 
  
$
(6,686,801
 
$
(6,686,436
Net income
     —          —          —          —          —          1,510,900       1,510,900  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Balance - March 31, 2022
  
 
455,096
 
  
 
46
 
  
 
3,188,696
 
  
 
319
 
  
 
  
 
  
 
(5,175,901
 
 
(5,175,536
Subsequent remeasurement of Class A ordinary shares subject to possible redemption amount
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
—  
 
     (93,539     (93,539
Net income
     —          —          —          —          —          200,685       200,685  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
Balance - June 30, 2022
  
 
455,096
 
  
$
46
 
  
 
3,188,696
 
  
$
319
 
  
$
—  
 
  
$
(5,068,755
)  
$
(5,068,390
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
 
FOR THE THREE MONTHS ENDED JUNE 30, 2021 AND FOR THE PERIOD FROM JANUARY 8, 2021
(INCEPTION) THROUGH JUNE 30, 2021 (UNAUDITED)
 
    
Ordinary Shares
   
Additional
         
Total
 
    
Class A
    
Class B
   
Paid-in
   
Accumulated
   
Shareholders’
 
    
Shares
    
Amount
    
Shares
   
Amount
   
Capital
   
Deficit
   
Deficit
 
Balance - January 8, 2021 (inception)
  
 
  
 
  
$
  
 
  
 
  
 
 
$
  
 
 
$
  
 
 
$
  
 
 
$
  
 
Issuance of Class B ordinary shares to Sponsor
     —          —          3,450,000       345       24,655                25,000  
Sale of units in private placement, less allocation to derivative warrant liabilities
     440,000        44                          4,210,756                4,210,800  
Remeasurement of Class A ordinary shares subject to possible redemption amount
     —          —          —         —         (4,235,411     (7,619,702     (11,855,113
Net income
     —          —          —         —         —         254,840       254,840  
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance - March 31, 2021
  
 
440,000
 
  
 
44
 
  
 
3,450,000
 
 
 
345
 
 
 
  
 
 
 
(7,364,862
 
 
(7,364,473
Forfeiture of Class B ordinary shares
     —          —          (261,304     (26     26       —         —    
Sale of units in private placement, less allocation to derivative warrant liabilities, gross (over-allotment)
     15,096        2        —         —         145,119       —         145,121  
Remeasurement of Class A ordinary shares subject to possible redemption amount (over-allotment)
     —          —          —         —         (145,145     (545,770     (690,915
Net income
     —          —          —         —         —         473,524       473,524  
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance - June 30, 2021
  
 
455,096
 
  
$
46
 
  
 
3,188,696
 
 
$
319
 
 
$
—  
 
 
$
(7,437,108
 
$
(7,436,743
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
3

EUROPEAN BIOTECH ACQUISITION CORP.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 
    
For The Six
Months Ended
June 30, 2022
   
For The Period
From January 8,
2021 (Inception)
Through
June 30, 2021
 
 
 
 
Cash Flows from Operating Activities:
                
Net income
   $ 1,711,585     $ 728,364  
Adjustments to reconcile net income to net cash used in operating activities:
                
Offering costs associated with derivative warrant liabilities
     —         314,846  
Change in fair value of derivative warrant liabilities
     (2,162,130     (1,343,760
Income from investments held in the Trust Account
     (185,089     (4,110
General and administrative expenses paid by Sponsor in exchange for issuance of Class B ordinary shares
     —         25,000  
Changes in operating assets and liabilities:
                
Prepaid expenses
     (127,461     (181,980
Accounts payable
     73,376       81,500  
Accrued expenses
     (142,064 )     32,954  
Deferred legal fees
     271,606       —    
    
 
 
   
 
 
 
Net cash used in operating activities
     (560,177     (347,186
    
 
 
   
 
 
 
Cash Flows from Investing Activities:
                
Cash deposited in Trust Account
              (127,547,843
    
 
 
   
 
 
 
Net cash used in investing activities
              (127,547,843
    
 
 
   
 
 
 
Cash Flows from Financing Activities:
                
Proceeds received from initial public offering, gross
              127,547,840  
Proceeds received from private placement, gross
     —         4,545,118  
Repayment of note payable to related parties
     —         (37,806
Offering costs paid
     —         (2,910,199
    
 
 
   
 
 
 
Net cash provided by financing activities
              129,144,953  
    
 
 
   
 
 
 
Net increase (decrease) in cash
     (560,177     1,249,924  
Cash - beginning of the period
     868,280       —    
    
 
 
   
 
 
 
Cash - end of the period
  
$
308,103
 
 
$
1,249,924
 
    
 
 
   
 
 
 
Supplemental disclosure of noncash activities:
                
Offering costs included in accrued expenses
   $ —       $ 96,003  
Offering costs included in accounts payable
   $ —       $ 15,000  
Offering costs paid by Sponsor under promissory note
   $ —       $ 37,806  
Deferred underwriting commissions
   $ —       $ 4,464,174  
Loan proceeds deposited in Trust Account
   $ —       $ 360,000  
Remeasurement of Class A ordinary shares subject to possible redemption
   $ 93,539     $ (12,546,029
The accompanying notes are an integral part of these unaudited condensed financial statements.
 
4

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
Note 1 - Description of Organization, and Business Operations
European Biotech Acquisition Corp. (the “Company”) was incorporated as a Cayman Islands exempted company on January 8, 2021. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.
As of June 30, 2022, the Company had not commenced any operations. All activity for the period from January 8, 2021 (inception) through June 30, 2022 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”) described below and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate
non-operating
income in the form of income from investments of the proceeds derived from the Initial Public Offering, along with gains and losses from the change in fair value of warrant liabilities. The Company has selected December 31 as its fiscal year end.
The Company’s sponsor is LSP Sponsor EBAC B.V., a Dutch limited liability company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on March 15, 2021. On March 18, 2021, the Company consummated its Initial Public Offering of 12,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”), at $10.00 per Unit, which generated gross proceeds of $120.0 million, and incurring offering costs of approximately $7.1 million, of which $4.5 million was for deferred underwriting commissions (see Note 3). The Company granted the underwriter a
45-day
option to purchase up to an additional 1,800,000 Units at the Initial Public Offering price to cover over-allotments, if any (the “Over-Allotment Units”). On May 3, 2021, the Company issued 754,784 Over-Allotment Units resulting in total gross proceeds of approximately $7.5 million, and the allotment option for the remaining 1,045,216 Over-Allotment Units expired.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 440,000 units (each, a “Private Placement Unit” and collectively, the “Private Placement Units”), at a price of $10.00 per Private Placement Unit with the Sponsor, generating gross proceeds of $4.4 million (see Note 4). If the over-allotment option would have been exercised in full, the Sponsor would have purchased an additional 36,000 Private Placement Warrants. On May 3, 2021, simultaneously with the issuance and sale of the Over-Allotment Units, the Company consummated the private placement with the Sponsor of 15,096 units (the “Additional Private Placement Units”), generating total proceeds of $150,960.
Upon the closing of the Initial Public Offering and the Private Placement, approximately $120.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement were placed in a trust account (“Trust Account”), located in the United States with Continental Stock Transfer & Trust Company acting as trustee, and will be invested only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule
2a-7
promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. In addition, the Sponsor and certain investors have advanced an aggregate amount of approximately $360,000 into the Trust Account to cover for the over-allotment option, if exercised. The over-allotment option was not exercised, so the excess funds were returned to such related parties. Upon partial exercise of the over-allotment, on May 4, 2021, the Company returned excess cash of $209,040 to the related parties, and placed the net proceeds of $7.4 million in the Trust Account.
The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust
 
5

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
Account (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.
The Company will provide the holders (the “Public Shareholders”) of its Public Shares with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay income taxes). The
per-share
amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 5).
These Public Shares were classified as temporary equity in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”). In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, only if a majority of the ordinary shares, represented in person or by proxy and entitled to vote thereon, voted at a shareholder meeting are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to the amended and restated memorandum and articles of association which the Company will adopt upon the consummation of the Initial Public Offering (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or vote at all. If the Company seeks shareholder approval in connection with a Business Combination, the initial shareholders (as defined below) agreed to vote their Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. Subsequent to the consummation of the Initial Public Offering, the Company adopted an insider trading policy which will require insiders to: (i) refrain from purchasing shares during certain blackout periods and when they are in possession of any material
non-public
information and (ii) to clear all trades with the Company’s legal counsel prior to execution. In addition, the initial shareholders agreed to waive their redemption rights with respect to their Founder Shares, private placement shares (the “Private Placement Shares”) underlying the Private Placement Units and Public Shares in connection with the completion of a Business Combination. Notwithstanding the foregoing, if the Company seeks shareholder approval of its Business Combination and does not conduct redemptions in connection with its Business Combination pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association will provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company.
The Company’s Sponsor, officers and directors (the “initial shareholders”) agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company’s obligation to provide holders of its Public Shares the right to have their shares redeemed in connection with a Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete its Business Combination within 24 months from the closing of the Initial Public Offering, or March 18, 2023 (the “Combination Period”) or with respect to any other provision relating to the rights of Public Shareholders (including extending the deadline for completing the initial Business Combination), unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment.
 
6

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
If the Company has not completed a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a
per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to consummate a Business Combination within the Combination Period.
The initial shareholders agreed to waive their liquidation rights with respect to the Founder Shares and Private Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account.
In order to protect the amounts held in the Trust Account, the Sponsor agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per Public Share due to reductions in the value of the trust assets. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (excluding the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.
Liquidity and Going Concern
As of June 30, 2022, the Company had approximately $308,000 in their operating bank account and working capital of approximately $47,000.
The Company’s liquidity needs through the consummation of the Initial Public Offering were satisfied through a payment of $25,000 from the Sponsor to purchase Founders Shares, and the loan proceeds from the Sponsor of $300,000 under the Note (Note 4). We repaid the Note in full on March 22, 2021. Subsequent to the consummation of the Initial Public Offering, our liquidity needs have been satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of our officers and directors may, but are not obligated to, provide us Working Capital Loans (as defined in Note 4). As of June 30, 2022 and December 31, 2021, there were no amounts outstanding under Working Capital Loans.
 
7

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
The Company does not believe the current cash on hand will be sufficient to cover obligations that come due within one year of release. Management has determined that the liquidity and, the mandatory liquidation and subsequent dissolution that will be required if the Company does not complete a business combination before March 18, 2023, raises substantial doubt about the Company’s ability to continue as a going concern. Although Management expects that it will be able to raise additional capital to support its planned activities and complete a business combination on or prior to March 18, 2023, it is uncertain whether it will be able to do so. No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after March 18, 2023. The condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Risks and Uncertainties
Management continues to evaluate the impact of the
COVID-19
pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.
In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. The specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form
10-Q
and Article 8 of Regulation
S-X
and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair presentation of the balances and results for the periods presented. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022, or for any future interim period.
The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form
10-K
for the year ended December 31, 2021, as filed with the SEC on March 31, 2022, which contains the audited financial statements and notes thereto. The accompanying financial information as of December 31, 2021, is derived from the audited financial statements presented in that Form
10-K.
Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
 
8

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company’s condensed financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of June 30, 2022 and December 31, 2021, the Company did not have any cash equivalents.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000, and cash held in Trust Account. As of June 30, 2022 and December 31, 2021, the Company has not experienced losses on these accounts.
Investments Held in Trust Account
The Company’s portfolio of investments, as of June 30, 2022 and December 31, 2021 is comprised of investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of mutual funds, the investments are recognized at fair value. Trading securities and investments in mutual funds are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in income from investments held in Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Through June 30, 2022, no amounts have been withdrawn from the Trust Account to pay taxes.
Financial Instruments
The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurement” equal or approximate the carrying amounts represented in the condensed balance sheets.
 
9

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
Fair Value Measurement
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
 
   
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
 
   
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
   
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Derivative warrant liabilities
The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC
815-40,
“Derivatives and Hedging-Contracts in Entity’s Own Stock” (“ASC
815-40”).
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is
re-assessed
at the end of each reporting period. The 4,251,595 warrants issued in connection with the Initial Public Offering (the “Public Warrants”) and the 151,699 Private Placement Warrants are recognized as derivative liabilities in accordance with ASC
815-40.
Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to
re-measurement
at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s condensed statements of operations. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model (see Note 9). For periods subsequent to the detachment of the Public Warrants from the Units, on May 13, 2021, the fair value of the Public Warrants is based on the observable listed price for such warrants. Since the Private Placement Warrants have substantially the same terms as the Public Warrants, the Company determined that the fair value of each Private Placement Warrant is equivalent to that of each Public Warrant.
Offering Costs Associated with the Initial Public Offering
Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liabilities were expensed as incurred and presented as
non-operating
expenses in the condensed statements of operations. Offering costs associated with the Class A common stock issued were charged against the carrying value of the shares of Class A ordinary shares upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as
non-current
liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
 
10

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
Class A Ordinary Shares Subject to Possible Redemption
The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC 480. Class A ordinary shares subject to mandatory redemption (if any) is classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares is classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, 12,754,784 shares of Class A ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s condensed balance sheets.
The Company has elected to recognize changes in redemption value immediately as they occur and adjust (for interest income and dissolution expenses) the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid-in capital (if available) and accumulated deficit. The change in the carrying value of redeemable shares of Class A ordinary shares resulted in charges against additional
paid-in
capital (to the extent available) and accumulated deficit.
Income Taxes
The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of June 30, 2022 and 2021. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s condensed financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Income Per Ordinary Share
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares subject to possible redemption and
non-redeemable
Class A ordinary shares and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares based on weighted average shares for the period. Net income per common share is calculated by dividing the net income by the weighted average number of ordinary shares outstanding for the respective period.
 
11

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
The calculation of diluted net income does not consider the effect of the warrants underlying the Units sold in the Initial Public Offering (including the consummation of the Over-allotment) and the private placement warrants to purchase an aggregate of 4,403,294 Class A ordinary shares in the calculation of diluted income per share, because their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted net income per share is the same as basic net income per share, related to the public warrants and private placement warrants, for the three and six months ended June 30, 2022, the three months ended June 30, 2021 and for the period from January 8, 2021 (inception) through June 30, 2021. Remeasurement associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value.
The Company has considered the effect of Class B ordinary shares that were excluded from weighted average number until the contingency was resolved, as they were contingent on the exercise of over-allotment option by the underwriters. Since the contingency was satisfied, the Company included these shares in the weighted average number as of the beginning of the period to determine the dilutive impact of these shares, resulting in a greater number of Class B ordinary shares being included in weighted average shares for the diluted calculation.
The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income per share for each class of ordinary shares:
 
    
For The Three Months Ended June 30,
 
    
2022
    
2021
 
    
Class A
    
Class A non-

redeemable
and Class B
    
Class A
    
Class A non-

redeemable
and Class B
 
Basic and diluted net income per ordinary share:
                                   
Numerator:
                                   
Allocation of net income, basic
   $ 156,093      $ 44,593      $ 371,037      $ 102,487  
Allocation of net income, diluted
   $ 156,093      $ 44,593      $ 370,913      $ 102,611  
Denominator:
                                   
Basic weighted average ordinary shares outstanding
     12,754,784        3,643,792        12,489,365        3,449,788  
Diluted weighted average ordinary shares outstanding
     12,754,784        3,643,792        12,489,365        3,455,096  
    
 
 
    
 
 
    
 
 
    
 
 
 
Basic net income per ordinary share
   $ 0.01      $ 0.01      $ 0.03      $ 0.03  
    
 
 
    
 
 
    
 
 
    
 
 
 
Diluted net income per ordinary share
   $ 0.01      $ 0.01      $ 0.03      $ 0.03  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
    
For The Six Months Ended June 30,
2022
    
For The Period From January 8,
2021 (Inception) Through June 30,
2021
 
  
Class A
    
Class A non-

redeemable and

Class B
    
Class A
    
Class A
non-redeemable

and Class B
 
Basic and diluted net income per ordinary share:
                                   
Numerator:
                                   
Allocation of net income, basic
   $ 1,331,267      $ 380,317      $ 515,384      $ 212,980  
Allocation of net income, diluted
   $ 1,331,267      $ 380,317      $ 498,591      $ 229,773  
Denominator:
                                   
Basic weighted average ordinary shares outstanding
     12,754,784        3,643,792        7,497,312        3,098,222  
Diluted weighted average ordinary shares outstanding
     12,754,784        3,643,792        7,497,312        3,455,096  
    
 
 
    
 
 
    
 
 
    
 
 
 
Basic net income per ordinary share
   $ 0.10      $ 0.10      $ 0.07      $ 0.07  
    
 
 
    
 
 
    
 
 
    
 
 
 
Diluted net income per ordinary share
   $ 0.10      $ 0.10      $ 0.07      $ 0.07  
    
 
 
    
 
 
    
 
 
    
 
 
 
Recent Accounting Standards
The Company’s management does not believe that any recently issued, but not yet effective, accounting standards
if
currently adopted would have a material effect on the accompanying condensed financial statements.
Note 3 - Initial Public Offering
On March 18, 2021, the Company consummated its Initial Public Offering of 12,000,000 Units, at $10.00 per Unit, generating gross proceeds of $120.0 million, and incurring offering costs of approximately $7.1 million, of which $4.5 million was for deferred underwriting commissions. The Company granted the underwriter a
45-day
option to purchase up to an additional 1,800,000 Units at the Initial Public Offering price to cover over-allotments. On May 3, 2021, the Company issued 754,784 Over-Allotment Units resulting in total gross proceeds of approximately $7.5 million, and the allotment option for the remaining 1,045,216 Over-Allotment units expired.
 
12

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
Each Unit consists of one Class A ordinary share, and
one-third
of one
redeemable warrant (each, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 8). On April 29, 2021, the Underwriters partially exercised the Over-allotment Option to purchase an additional 754,784 units (the “Option Units”). Each Option Unit consists of one Class A Ordinary Share and
one-third
of one Warrant.
On May 3, 2021, the Company completed the sale of the Option Units to the Underwriters for net proceeds of $7,396,883 in the aggregate after deducting the underwriter discount (the “Option Unit Proceeds”).
Note 4 - Related Party Transactions
Founder Shares
On January 18, 2021, the Sponsor paid $25,000 to cover certain expenses of the Company in consideration of 2,875,000 Class B ordinary shares, par value $0.0001, (the “Founder Shares”). On March 15, 2021, the Company effected a
6-for-5
share split, resulting in an aggregate of 3,450,000 Class B ordinary shares outstanding. Prior to the Initial Public Offering, the Sponsor transferred 25,000 Founder Shares to two of the Company’s independent directors. These 50,000 shares are not subject to forfeiture in the event the underwriters’ over-allotment option is not exercised. The Sponsor agreed to forfeit up to 450,000 Founder Shares to the extent that the over-allotment option was not exercised in full by the underwriters, so that the Founder Shares will represent 20.0% of the Company’s issued and outstanding ordinary shares (excluding the Private Placement Shares and assuming the initial shareholders do not purchase any Units in the Initial Public Offering) after the Initial Public Offering. On May 3, 2021, the Company issued 754,784 Over-Allotment Units resulting in the forfeiture of 261,304 Class B ordinary shares during the three months ended June 30, 2021.
The sale or transfers of the Founder Shares to members of the Company’s board of directors, as described above, is within the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The Founder Shares were effectively sold or transferred subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founder Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. Stock-based compensation would be recognized at the date a Business Combination is considered probable in an amount equal to the number of Founder Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founder Shares. As of June 30, 2022, the Company determined that a Business Combination is not considered probable until the business combination is completed, and therefore, no stock-based compensation expense has been recognized.
The initial shareholders agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
30-trading
day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property.
Private Placement Units
Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 440,000 Private Placement Units, at a price of $10.00 per Private Placement Unit with the Sponsor, which generated gross proceeds of $4.4 million. If the over-allotment option is exercised in full, the Sponsor will purchase an additional 36,000 Private Placement Warrants. Simultaneously with the closing of the Over-Allotment on May 3, 2021, the
 
13

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 15,096 Private Placement Units at $10.00 per additional Private Placement Unit (the “Additional Private Placement Units”), generating additional gross proceeds of approximately $151,000. The Private Placement Units (including the Private Placement Shares, the Private Placement Warrants (as defined below) and Class A ordinary shares issuable upon exercise of such warrants) will not be transferable or salable until 30 days after the completion of the initial Business Combination.
Each Private Placement Unit consists of one
non-redeemable
Class A ordinary share and
one-third
of a private placement warrant. Each whole private placement warrant underlying the Private Placement Units (the “Private Placement Warrants”) is exercisable for one whole Class A ordinary share at a price of $11.50 per share. A portion of the proceeds from the Private Placement Units was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Units and the underlying securities will expire worthless. The Private Placement Warrants will be
non-redeemable
(except as described in Note 6 below under “Redemption of warrants for Class A ordinary shares when the price per Class A ordinary share equals or exceeds $10.00”) and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.
The Sponsor and the Company’s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Units until 30 days after the completion of the initial Business Combination.
Due to Related Parties
On January 18, 2021, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover for expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan was
non-interest
bearing and payable upon the completion of the Initial Public Offering. The Company borrowed approximately $38,000 under the Note. The Company repaid the Note in full on March 22, 2021. Subsequent to the repayment, the facility was no longer available to the Company.
In addition, the Sponsor and certain investors have advanced an aggregate amount of approximately $360,000 into the Trust Account to cover for the over-allotment option, if exercised. If the over-allotment option was not exercised, the excess funds would have been returned to such related parties. Upon partial exercise of the over-allotment, on May 4, 2021, the Company returned excess cash of $209,040 to the related parties.
In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lenders’ discretion, up to $1.5 million of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. As of June 30, 2022 and December 31, 2021, the Company had no outstanding borrowings under the Working Capital Loans.
Administrative Support Agreement
Commencing on the date that the securities were first listed on the Nasdaq through the earlier of consummation of the initial Business Combination or the Company’s liquidation, the Company agreed to reimburse the Sponsor for office space, administrative and support services provided to the Company in the amount of $20,000 per month. During the three months ended June 30, 2022 and 2021, the Company incurred approximately $60,000 of such fees, which are recognized in general and administrative expenses-related party, in the accompanying condensed statements
 
14

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
of operations
.
 During the six months ended June 30, 2022 and the period from January 8, 2021 (inception) through June 30, 2021, the Company incurred approximately $120,000 and $80,000 of such fees, which are recognized in general and administrative expenses-related party, in the accompanying condensed statements of operations, respectively. As of June 30, 2022
and
December 31, 2021, there was $120,000 and $0 of such fees in accounts payable on the condensed balance sheets, respectively.
In addition, the Sponsor, officers and directors, or their respective affiliates will be reimbursed for any
out-of-pocket
expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The Company’s audit committee will review on a quarterly basis all payments that were made by the Company to the Sponsor, executive officers or directors, or their affiliates. Any such payments prior to an initial Business Combination will be made using funds held outside the Trust Account.
Note 5 - Commitments and Contingencies
Registration Rights
The holders of the Founder Shares, Private Placement Units, Private Placement Warrants, Class A ordinary shares underlying the Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration and shareholder rights agreement signed upon the effective date of the Initial Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registered such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. However, the registration and shareholder rights agreement provide that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
The underwriters were entitled to an underwriting discount of $0.20 per Unit, or $2.6 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or $4.5 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
On May 3, 2021, the underwriters partially exercised their over-allotment option. As a result, the underwriters were entitled to an underwriting discount of approximately $151,000, which was paid upon closing of the over-allotment. In addition, $264,000 will be payable to the underwriters for deferred underwriting commissions.
Note 6 - Class A Ordinary Shares Subject to Possible Redemption
The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 200,000,000 Class A ordinary shares with a par value of $0.0001 per share. Holder of the Company’s Class A ordinary shares are entitled to one vote for each share. As of June 30, 2022 and December 31, 2021, there were 12,754,784 Class A ordinary shares subject to possible redemption.
 
15

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
The Class A ordinary shares subject to possible redemption (including the over-allotment) reflected on the condensed balance sheets is reconciled on the following table:
 
Gross proceeds from Initial Public Offering
  
$
127,547,840
 
Less:
  
     
Fair value of Public Warrants at issuance
  
 
(5,331,850
Offering costs allocated to Class A ordinary shares subject to possible redemption
  
 
(7,214,179
Plus:
  
     
Remeasurement of Class A ordinary shares subject to possible redemption amount
  
 
12,546,029
 
 
  
 
 
 
Class A ordinary shares subject to possible redemption, December 31, 2021
  
 
127,547,840
 
Subsequent remeasurement of Class A ordinary shares subject to possible redemption amount
  
 
93,539
 
 
  
 
 
 
Class A ordinary shares subject to possible redemption, June 30, 2022
  
$
127,641,379
 
 
  
 
 
 
Note 7 - Shareholders’ Deficit

Preference Shares
The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of June 30, 2022 and December 31, 2021, there were no preference shares issued or outstanding.
Class A Ordinary Shares
The Company is authorized to issue 200,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of June 30, 2022 and December 31, 2021, there were 13,209,880 Class A ordinary shares issued and outstanding, of which 12,754,784 shares were subject to possible redemption and are classified as temporary equity (see Note 6).
Class B Ordinary Shares
The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. As of June 30, 2022 and December 31, 2021, the Company had 3,188,696 Class B ordinary shares issued and outstanding (See Note 4). Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders except as required by law. The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares underlying the Private Placement Units) upon completion of the Initial Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities (as defined herein) or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Company’s Sponsor, its affiliates or any member of the Company’s management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than
one-to-one.
Note 8 - Derivative Warrant Liabilities
As of June 30, 2022 and December 31, 2021, the Company had 4,251,595 Public Warrants and the 151,699 Private Placement Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering. The Company agreed that as soon as practicable,
but
in no event later than 20 business days after the closing of the

16

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
initial
 Business Combination, the Company will use its commercially reasonable efforts to file with the SEC a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60
business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a registration statement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, but the Company will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.
The
warrant has an exercise price of $11.50, subject to adjustments as described herein, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described under “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” and “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price under “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.
The Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, except as described below. The Private Placement Warrants (including the Class A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination (except pursuant to limited exceptions to the officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants) and they will not be redeemable by the Company (except as described under “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00”) so long as they are held by the Sponsor or its permitted transferees (except as otherwise set forth herein). The Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. If the private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants.
Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00.
Once the warrants become exercisable, the Company may redeem the outstanding warrants (except with respect to the Private Placement Warrants):
 
   
in whole and not in part;
 
   
at a price of $0.01 per warrant;
 
   
upon a minimum of 30 days’ prior written notice of redemption; and
 
17

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
   
if, and only if, the last reported sales price (the “closing price”) of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a
30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.
The Company will not redeem the warrants as described above unless an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants is effective and a current prospectus relating to those Class A ordinary shares is available throughout the
30-day
redemption period.
Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00.
Once the warrants become exercisable, the Company may redeem the outstanding warrants:
 
   
in whole and not in part;
 
   
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption
provided
that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares;
 
   
if, and only if, the closing price of Class A ordinary shares equals or exceeds $10.00 per Public Share (as adjusted) for any 20 trading days within the
30-trading
day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and
 
   
if the closing price of the Class A ordinary shares for any 20 trading days within a
30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above.
The “fair market value” of Class A ordinary shares for the above purpose shall mean the volume weighted average price of Class A ordinary shares during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no event will the warrants be exercisable in connection with this redemption feature for more than 0.361 Class A ordinary shares per warrant (subject to adjustment).
If the Company has not completed the initial Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
Note 9 - Fair Value Measurements
The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value.
 
June 30, 2022
 
Description
  
Quoted Prices in Active

Markets

(Level 1)
 
  
Significant Other

Observable Inputs

(Level 2)
 
  
Significant Other

Unobservable Inputs

(Level 3)
 
Assets:
  
     
  
     
  
     
Investments held in Trust Account - Money Market Funds
   $ 127,741,378      $         $     
Liabilities:
                          
Derivative warrant liabilities - Public warrants
   $ 463,220      $         $     
Derivative warrant liabilities - Private placement warrants
   $         $ 16,630      $     
18

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
December 31, 2021
 
Description
  
Quoted Prices in Active

Markets

(Level 1)
    
Significant Other

Observable Inputs

(Level 2)
    
Significant Other

Unobservable Inputs

(Level 3)
 
Assets:
                          
Investments held in Trust Account - Money Market Funds
   $ 127,556,289      $         $     
Liabilities:
                          
Derivative warrant liabilities - Public warrants
   $ 2,550,960      $         $     
Derivative warrant liabilities - Private placement warrants
   $         $ 91,020      $     
Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. The estimated fair value of the Public Warrants was transferred from a Level 3 measurement to a Level 1 measurement in May 2021, when the Public Warrants were separately listed and traded in an active market. The estimated fair value of the Private Placement Warrants was transferred from a Level 3 measurement to a Level 2 measurement in May 2021, as the transfer of Private Placement Warrants to anyone who is not a permitted transferee would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, so the Company determined that the fair value of each Private Placement Warrant is equivalent to that of each Public Warrant.
Level 1 assets include investments in money market funds that invest solely in U.S. government securities. The Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.
The following table provides quantitative information regarding Level 3 fair value measurements inputs at the initial measurement dates for the Public Warrants and Private Placement Warrants:
 
    
March 18, 2021
   
May 3, 2021
 
Exercise price
   $ 11.50     $ 11.50  
Stock price
   $ 9.58     $ 9.59  
Volatility
     21.7     18.6
Term
     5.5       5.5  
Risk-free rate
     0.95     0.95
The Company utilized a Monte-Carlo simulation to estimate the fair value of the Public and Private Placement Warrants at the issuance dates, and as of March 31, 2021. For the three months ended June 30, 2022 and 2021, the Company recognized a gain resulting from changes in the fair value of derivative warrant liabilities of approximately $0.4 million and $0.7 
million, respectively, which is presented in the accompanying condensed statements of operations. For the six months ended June 30, 2022 and for the period from January 8, 2021 (inception) through June 30, 2021, the Company recognized a gain resulting from changes in the fair value of derivative warrant liabilities of approximately
 $2.2 million and $1.3 
million, respectively, which is presented in the accompanying condensed statements of operations. 
The change in the fair value of the derivative warrant liabilities (prior to the over-allotment), measured using Level 3 inputs, for the period from January 8, 2021 (inception) through June 30, 2021 is summarized as
follows:
 
Derivative warrant liabilities at January 8, 2021 (inception)
   $     
Issuance of Public and Private Warrants
     5,229,200  
Change in fair value of derivative warrant liabilities
     (663,470
    
 
 
 
Derivative warrant liabilities at March 31, 2021
     4,565,730  
Issuance of Public Warrants - over-allotment
     291,850  
Issuance of Private Placement Warrants - over-allotment
     5,840  
Transfer of Public Warrants to Level 1
     (4,691,850
Transfer of Private Placement Warrants to Level 2
     (171,570
Derivative warrant liabilities at June 30, 2021
   $     
 
19

EUROPEAN BIOTECH ACQUISITION CORP.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
JUNE 30, 2022
 
Note 10 - Subsequent Events
The Company has evaluated subsequent events and transactions that occurred up to the date the condensed financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.
 
20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
References to the “Company,” “our,” “us” or “we” refer to European Biotech Acquisition Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form
10-Q
includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue to be consistently below,” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this Form
10-Q.
Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission (“SEC”) filings.
Overview
We are a blank check company incorporated on January 8, 2021 as a Cayman Islands exempted company formed for the purpose of effecting a Business Combination. We will not be limited to a particular industry or geographic region in our identification and acquisition of a target company.
On March 18, 2021, we consummated our Initial Public Offering of 12,000,000 Units, at $10.00 per Unit, generating gross proceeds of $120.0 million, and incurring offering costs of approximately $7.1 million, of which $4.5 million was for deferred underwriting commissions (see Note 3 to our condensed financial statements). We granted the underwriter a
45-day
option to purchase up to an additional 1,800,000 Units at the Initial Public Offering price to cover over-allotments, if any. On April 29, 2021, the underwriters partially exercised the over-allotment option, and the closing of the issuance and sale of the additional 754,784 Over-Allotment Units occurred on May 3, 2021. The issuance by the Company of the Over-Allotment Units at a price of $10.00 per unit resulted in total gross proceeds of approximately $7.5 million.
Simultaneously with the closing of the Initial Public Offering, we consummated the Private Placement of 440,000 units, at a price of $10.00 per Private Placement Unit with the Sponsor, generating gross proceeds of $4.4 million (see Note 4 to our condensed financial statements included in this Quarterly Report on Form
10-K
for the year ended December 31, 2021). If the over-allotment option is exercised in full, the Sponsor will purchase an additional 36,000 Private Placement Units. Simultaneously with the issuance and sale of the Option Units, the Company consummated the private placement with the Sponsor of 15,096 Additional Private Placement Units, generating total proceeds of $150,960.
Upon the closing of the Initial Public Offering and the Private Placement, approximately $120.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement were placed in a Trust Account, located in the United States with Continental Stock Transfer & Trust Company acting as trustee, and will be invested only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act, having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule
2a-7
promulgated under the Investment Company Act which invests only in direct U.S. government treasury obligations, as determined by us, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. In addition, the Sponsor and certain investors have advanced an aggregate amount of approximately $360,000 into the Trust Account to cover for the over-allotment option, if exercised. If the over-allotment option is not exercised, the excess funds will be returned to such related parties. Upon partial exercise of the over-allotment, on May 4, 2021, the Company returned excess cash of $209,040 to the related parties.
 
21

Our management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that we will be able to complete a Business Combination successfully.
We must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, we will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.
If we are unable to complete a Business Combination within the Combination Period, we will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a
per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to our warrants, which will expire worthless if we fail to consummate a Business Combination within the Combination Period.
As of June 30, 2022, we held cash of approximately $308,000, current liabilities of approximately $437,000 and deferred underwriting commissions of approximately $4.5 million. Further, we expect to continue to incur significant costs in the pursuit of our initial business combination. We cannot assure you that our plans to complete an initial business combination will be successful.
RESULTS OF OPERATIONS
We have neither engaged in any operations (other than searching for a Business Combination after our Initial Public Offering) nor generated any revenues to date. Our entire activity since inception up to June 30, 2022 related to our formation, the preparation for the Initial Public Offering, and since the closing of the Initial Public Offering, the search for a prospective initial Business Combination. We will not be generating any operating revenues until the closing and completion of our initial Business Combination, at the earliest. We generate non-operating income in the form of income from investments held in the Trust Account, and change in fair value of warrant liability. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in our search for and completion of a Business Combination.
For the three months ended June 30, 2022, we had net income of approximately $201,000, which consisted of approximately $401,000 of
non-operating
gain from changes in fair value of derivative warrant liabilities and approximately $172,000 in income from investments held in the Trust Account, partially offset by approximately $372,000 of general and administrative expenses.
For the three months ended June 30, 2021, we had we had net income of approximately $474,000 which consisted of approximately $680,000 of
non-operating
gain from changes in fair value of derivative warrant liabilities and approximately $4,000 in income from investments held in the Trust Account, partially offset by approximately $195,000 of general and administrative expenses, and a
non-operating
expense of approximately $16,000 related to offering costs for derivative warrant liabilities.
For the six months ended June 30, 2022, we had net income of approximately $1.7 million, which consisted of approximately $2.2 million of
non-operating
gain from changes in fair value of derivative warrant liabilities and approximately $185,000 in income from investments held in the Trust Account, partially offset by approximately $665,000 of general and administrative expenses.
 
22

For the period from January 8, 2021 (inception) through June 30, 2021, we had we had net income of approximately $728,000, which consisted of approximately $1.3 million of
non-operating
gain from changes in fair value of derivative warrant liabilities and approximately $4,000 in income from investments held in the Trust Account, partially offset by approximately $305,000 of general and administrative expenses, and a
non-operating
expense of approximately $315,000 related to offering costs for derivative warrant liabilities.
Liquidity and Going Concern
As of June 30, 2022, we had approximately $308,000 in our operating bank account and working capital of approximately $47,000.
Our liquidity needs through the consummation of the Initial Public Offering were satisfied through a payment of $25,000 from the Sponsor to purchase Founders Shares, and the loan proceeds from the Sponsor of $300,000 under the Note (Note 4 to our condensed financial statements). We repaid the Note in full on March 22, 2021. Subsequent to the consummation of the Initial Public Offering, our liquidity needs have been satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of our officers and directors may, but are not obligated to, provide us Working Capital Loans (as defined in Note 4). As of June 30, 2022 and December 31, 2021, there were no amounts outstanding under Working Capital Loans.
Management does not believe the current cash on hand will be sufficient to cover obligations that come due within one year of release. Management has determined that the liquidity, the mandatory liquidation and subsequent dissolution that will be required if the Company does not complete a business combination before March 18, 2023 raises substantial doubt about the Company’s ability to continue as a going concern. Although Management expects that it will be able to raise additional capital to support its planned activities and complete a business combination on or prior to March 18, 2023, it is uncertain whether it will be able to do so. No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after March 18, 2023. The condensed financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
We continue to evaluate the impact of the
COVID-19
pandemic and have concluded that the specific impact is not readily determinable as of the date of the condensed balance sheets. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Contractual Obligations
Administrative Services Agreement
Commencing on the date that the Company’s securities were first listed on the Nasdaq through the earlier of consummation of the initial Business Combination and the Company’s liquidation, the Company agreed to pay affiliates of the Sponsor a total of $20,000 per month for office space, administrative and support services.
Registration Rights
The holders of the Founder Shares, Private Placement Units, Class A ordinary shares underlying the Private Placement Units and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) were entitled to registration rights pursuant to a registration and shareholder rights agreement signed upon the effective date of the Initial Public Offering. The holders of these securities were entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. However, the registration and shareholder rights agreement provide that we will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period. We will bear the expenses incurred in connection with the filing of any such registration statements.
 
23

Underwriting Agreement
The underwriters were entitled to an underwriting discount of $0.20 per Unit, or $2.4 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or $4.2 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.
On May 3, 2021 the underwriters partially exercised their over-allotment option. As a result, the underwriters were entitled to an additional underwriting discount of approximately $151,000, which was paid upon closing of the over-allotment. In addition, $264,000 will be payable to the underwriters for deferred underwriting commissions.
Critical Accounting Policies
This management’s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our condensed financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and the disclosure of contingent assets and liabilities in our condensed financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair value of financial instruments and accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The Company determined that there have been no material changes to the critical accounting policies disclosed in our Annual Report on Form
10-K
for the period ended December 31, 2021, filed with the SEC on March 31, 2022.
Recent Accounting Standards
Our management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.
Off-Balance
Sheet Arrangements
As of June 30, 2022 and December 31, 2021, we did not have any
off-balance
sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation
S-K.
JOBS Act
The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for
non-emerging
growth companies. As a result, the condensed financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of
non-emerging
growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the condensed financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.
 
24

Item 3.
Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Rule
12b-2
of the Exchange Act and are not required to provide the information otherwise required under this item.
 
Item 4.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended June 30, 2022, as such term is defined in Rules
13a-15(e)
and
15d-15(e)
under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer have concluded that during the period covered by this report, our disclosure controls and procedures were effective as of June 30, 2022.
Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the fiscal quarter ended June 30, 2022 covered by this Quarterly Report on Form
10-Q
that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, except for the remediation of the material weakness discussed below during the quarter ended June 30, 2022.
Remediation of a Material Weakness in Internal Control over Financial Reporting
We recognize the importance of the control environment as it sets the overall tone for the Company and is the foundation for all other components of internal control. Consequently, we designed and implemented remediation measures to address the material weakness previously identified in fiscal year 2021 and reported in our previous periodic filings with the SEC on Form 10-K and Form 10-Q, and enhanced our internal control over financial reporting. In light of the material weakness, we enhanced our processes and the related internal controls to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our condensed financial statements, including providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. The foregoing actions, which we believe remediated the material weakness in internal control over financial reporting, were completed prior to June 30, 2022.
PART
II-OTHER
INFORMATION
 
Item 1.
Legal Proceedings
None.
 
25

Item 1A.
Risk Factors
As of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in our Annual Report on Form
10-K
and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, as filed with the SEC. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.
 
26

Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.
None.
 
Item 3.
Defaults upon Senior Securities
None.
 
Item 4.
Mine Safety Disclosures
Not applicable.
 
Item 5.
Other Information.
None.
 
Item 6.
Exhibits.
 
Exhibit
Number
  
Description
31.1*    Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*    Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**    Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**    Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS    XBRL Instance Document
101.SCH    XBRL Taxonomy Extension Schema Document
101.CAL    XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF    XBRL Taxonomy Extension Definition Linkbase Document
101.LAB    XBRL Taxonomy Extension Label Linkbase Document
101.PRE    XBRL Taxonomy Extension Presentation Linkbase Document
Exhibit 104    Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
 
*
Filed herewith.
**
These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
 
27

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this 15th day of August 2022
 
EUROPEAN BIOTECH ACQUISITION CORP.
By:  
/s/ Eduardo Bravo Fernandez de Araoz
Name:   Eduardo Bravo Fernandez de Araoz
Title:  
Chief Executive Officer
(Principal Executive Officer)
 
28

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Eduardo Bravo Fernandez de Araoz, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 of European Biotech Acquisition Corp.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

[Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942];

 

  c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: August 15, 2022     By:  

/s/ Eduardo Bravo Fernandez de Araoz

      Eduardo Bravo Fernandez de Araoz
      Chief Executive Officer
      (Principal Executive Officer)

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Koen Sintnicolaas, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 of European Biotech Acquisition Corp.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

[Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942];

 

  c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: August 15, 2022     By:  

/s/ Koen Sintnicolaas

      Koen Sintnicolaas
     

Chief Financial Officer

(Principal Financial and Accounting Officer)

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of European Biotech Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Eduardo Bravo Fernandez de Araoz, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 15, 2022

 

/s/ Eduardo Bravo Fernandez de Araoz

Name:   Eduardo Bravo Fernandez de Araoz
Title:   Chief Executive Officer
  (Principal Executive Officer)

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of European Biotech Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Koen Sintnicolaas, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 15, 2022      
   

/s/ Koen Sintnicolaas

    Name:   Koen Sintnicolaas
    Title:   Chief Financial Officer
    (Principal Financial and Accounting Officer)


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings